Drug
XZP-3621
XZP-3621 is a pharmaceutical drug with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
2
50%
Ph phase_2
1
25%
Ph phase_3
1
25%
Phase Distribution
2
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(2)
Other(2)
Detailed Status
unknown2
Completed2
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 12 (50.0%)
Phase 21 (25.0%)
Phase 31 (25.0%)
Trials by Status
unknown250%
completed250%
Recent Activity
0 active trials
Showing 4 of 4
completedphase_1
A Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung Cancer
NCT05055232
completedphase_1
Food Effect and Mass Balance Study of XZP-3621 Tablets
NCT05034120
unknownphase_2
A Study of XZP-3621 in Chinese Patients With ALK Positive NSCLC
NCT05482087
unknownphase_3
A Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus Crizotinib
NCT05204628
Clinical Trials (4)
Showing 4 of 4 trials
NCT05055232Phase 1
A Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung Cancer
NCT05034120Phase 1
Food Effect and Mass Balance Study of XZP-3621 Tablets
NCT05482087Phase 2
A Study of XZP-3621 in Chinese Patients With ALK Positive NSCLC
NCT05204628Phase 3
A Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus Crizotinib
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4